Tenofovir (Viread)

Tenofovir (Viread) Produces Continued HBV Suppression through 96 Weeks in HBeAg Positive and Negative Patients: Studies 102 and 103 - 11-05/2008

Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - 11-05/2008

Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD - 11-05/2008

Tenofovir is Equally Active In Vitro Against Wild-type HBV Clinical Isolates of Genotypes A-H - 11-05/2008

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA - 11-05/2008

PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B - 11-05/2008

Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103 - 11-05/2008

Tenofovir (Viread) Effective against Entecavir-resistant Hepatitis B Virus - 8/26/2008

FDA Approves Gilead's Tenofovir (Viread) for Treatment of Chronic Hepatitis B - 8/15/08

Pharmasset Announces New Trial to Study Clevudine plus Tenofovir (Viread) for Chronic Hepatitis B - 7/11/08

Tenofovir (Viread) Demonstrates Good Efficacy and Tolerability in Hepatitis B Patients with Compensated Liver Cirrhosis - 5/13/08

Tenofovir May Be More Effective and Less Expensive than Lamivudine (Epivir-HBV) and Adefovir (Hepsera) as First-line Treatment for HBeAg- Chronic Hepatitis B - 5/09/08

Tenofovir (Viread) Is Effective in Chronic Hepatitis B Patients with Prior Nucleoside/nucleotide Experience - 5/09/08


Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) - 4/29/08
P Marcellin and others. EASL 2008.

The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-Naïve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) - 4/29/08
M Manns and others. EASL 2008.

Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103) - 4/29/08
J Heathcote and others. EASL 2008.

Lack Of Infl uence Of Baseline Genotype On Antiviral Response In Subjects With Chronic Hepatitis B Infection Receiving Tenofovir DF 300 MG QD For 1 Year - 4/29/08
E Gane and others. EASL 2008.

Cost-Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (Tenofovir) in HBeAg Negative Patients with Chronic Hepatitis-B in Italy and France - 4/29/08
B Denzi and others. EASL 2008.

Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis - 4/29/08
M Buti and others. EASL 2008.


Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - 4/29/08
T Berg and others. EASL 2008.

European Commission Approves Tenofovir (Viread) for Chronic Hepatitis B - 4/29/08

Tenofovir (Viread) Is Effective after Adefovir (Hepsera), but Not Vice Versa - 2/01/08

Tenofovir (Viread) Is Superior to Adefovir (Hepsera) at 48 Weeks for Both HBeAg Positive and HBeAg Negative Patients with Chronic Hepatitis B - 11/09/07

Gilead Sciences Seeks U.S. and European Marketing Approval for Tenofovir (Viread) for Treatment of Chronic Hepatitis B - 10/16/07

Second Phase III Study Confirms Tenofovir (Viread) Works as Well as Adefovir (Hepsera) for Treatment of Chronic Hepatitis B    - 6/29/07

Second Phase III Study Confirms Tenofovir (Viread) Works as Well as Adefovir (Hepsera) for Treatment of Chronic Hepatitis B - 6/21/07

Tenofovir Works as Well as Adefovir for Chronic Hepatitis B - 6/15/07

HAART Regimens Containing Tenofovir Plus Lamivudine or Emtricitabine Work Best for HIV-HBV Coinfected Patients  - 5/01/07

Emergence of Tenofovir-resistant Mutations Is Uncommon in HIV-HBV Coinfected Patients - 4/3/07

Long-term Lamivudine plus Tenofovir Is Safe and Effective in HIV-HBV Coinfected Patients  - 3/27/07

Hepatitis B Virus Plasma Dynamics in HIV-HBV Coinfected Patients Receiving Adefovir or Tenofovir  - 3/16/07

Pre-exposure Prophylaxis with Emtricitabine Plus Tenofovir Protects Monkeys against SHIV Infection  - 3/16/07